MA55298A - Compositions pharmaceutiques contenant des anticorps anti-lingo-1 - Google Patents
Compositions pharmaceutiques contenant des anticorps anti-lingo-1Info
- Publication number
- MA55298A MA55298A MA055298A MA55298A MA55298A MA 55298 A MA55298 A MA 55298A MA 055298 A MA055298 A MA 055298A MA 55298 A MA55298 A MA 55298A MA 55298 A MA55298 A MA 55298A
- Authority
- MA
- Morocco
- Prior art keywords
- lingo
- antibodies
- pharmaceutical compositions
- compositions containing
- containing anti
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816668P | 2019-03-11 | 2019-03-11 | |
| US201962817323P | 2019-03-12 | 2019-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55298A true MA55298A (fr) | 2022-01-19 |
Family
ID=70190131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055298A MA55298A (fr) | 2019-03-11 | 2020-03-10 | Compositions pharmaceutiques contenant des anticorps anti-lingo-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220144945A1 (enExample) |
| EP (1) | EP3938395A1 (enExample) |
| JP (1) | JP2022524814A (enExample) |
| KR (1) | KR20210136063A (enExample) |
| CN (1) | CN113661179A (enExample) |
| AU (1) | AU2020234943A1 (enExample) |
| BR (1) | BR112021017644A2 (enExample) |
| CA (1) | CA3133072A1 (enExample) |
| IL (1) | IL286162A (enExample) |
| MA (1) | MA55298A (enExample) |
| MX (1) | MX2021010420A (enExample) |
| TW (1) | TW202103732A (enExample) |
| UY (1) | UY38605A (enExample) |
| WO (1) | WO2020185750A1 (enExample) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
| JP3593343B2 (ja) | 1993-02-09 | 2004-11-24 | バイオジェン インコーポレイテッド | インシュリン依存型糖尿病の治療 |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| PL378582A1 (pl) | 2003-03-19 | 2006-05-02 | Biogen Idec Ma Inc. | Białko wiążące receptor Nogo |
| EP2474317A1 (en) | 2004-06-24 | 2012-07-11 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| EP2350649A4 (en) * | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
| MA45668A (fr) * | 2016-07-13 | 2019-05-22 | Biogen Ma Inc | Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |
| US11845798B2 (en) * | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| SMT202300129T1 (it) * | 2017-08-22 | 2023-05-12 | Biogen Ma Inc | Composizioni farmaceutiche contenenti anticorpi anti-beta amiloide |
-
2020
- 2020-03-10 AU AU2020234943A patent/AU2020234943A1/en not_active Abandoned
- 2020-03-10 CN CN202080027211.8A patent/CN113661179A/zh active Pending
- 2020-03-10 WO PCT/US2020/021842 patent/WO2020185750A1/en not_active Ceased
- 2020-03-10 EP EP20717406.1A patent/EP3938395A1/en not_active Withdrawn
- 2020-03-10 BR BR112021017644A patent/BR112021017644A2/pt not_active Application Discontinuation
- 2020-03-10 KR KR1020217031856A patent/KR20210136063A/ko not_active Withdrawn
- 2020-03-10 CA CA3133072A patent/CA3133072A1/en active Pending
- 2020-03-10 TW TW109107890A patent/TW202103732A/zh unknown
- 2020-03-10 UY UY0001038605A patent/UY38605A/es not_active Application Discontinuation
- 2020-03-10 US US17/437,634 patent/US20220144945A1/en not_active Abandoned
- 2020-03-10 JP JP2021554699A patent/JP2022524814A/ja active Pending
- 2020-03-10 MA MA055298A patent/MA55298A/fr unknown
- 2020-03-10 MX MX2021010420A patent/MX2021010420A/es unknown
-
2021
- 2021-09-05 IL IL286162A patent/IL286162A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113661179A (zh) | 2021-11-16 |
| MX2021010420A (es) | 2021-11-12 |
| IL286162A (en) | 2021-10-31 |
| JP2022524814A (ja) | 2022-05-10 |
| EP3938395A1 (en) | 2022-01-19 |
| UY38605A (es) | 2020-09-30 |
| BR112021017644A2 (pt) | 2021-11-16 |
| TW202103732A (zh) | 2021-02-01 |
| AU2020234943A1 (en) | 2021-09-23 |
| CA3133072A1 (en) | 2020-09-17 |
| KR20210136063A (ko) | 2021-11-16 |
| WO2020185750A1 (en) | 2020-09-17 |
| US20220144945A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| EP3565550A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM | |
| EP3621621A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| EP3914252A4 (en) | PHARMACEUTICAL COMPOSITION OF NILOTINIB | |
| EP3548000A4 (en) | PHARMACEUTICAL COMPOSITIONS OF ATROPINE | |
| EP3817722A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM | |
| EP3449940A4 (en) | ANTIBODY PREPARATION | |
| MA56049A (fr) | Formulations stabilisées contenant des anticorps anti-angptl3 | |
| EP3881846A4 (en) | PHARMACEUTICAL COMPOSITION WITH PARP INHIBITORS | |
| MA55362A (fr) | Formulations stabilisées contenant des anticorps anti-il-33 | |
| EP3391904A4 (en) | PHARMACEUTICAL COMPOSITION WITH ANTIBODY TO THE HUMAN TSLP RECEPTOR | |
| MA49116A (fr) | Compositions pharmaceutiques contenant de l'insuline | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| EP4037711A4 (en) | COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES | |
| EP4122483A4 (en) | Oral pharmaceutical composition | |
| EP3946316A4 (en) | PHARMACEUTICAL CANNABIDIOL COMPOSITIONS | |
| EP3699199A4 (en) | Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same | |
| MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
| EP3851121A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING HUMAN MONOCLONAL ANTI-IL-33 ANTIBODIES | |
| EP3325456A4 (en) | CRYSTAL FORMS OF TETRA-HYDRO-N, N-DIMETHYL-2,2-DIPHENYL-3-FURANOMETHANAMINE HYDROCHLORIDE, METHOD FOR THE PREPARATION OF SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
| MX2019003010A (es) | Composición farmacéutica de clozapina de liberación prolongada. | |
| MA53812A (fr) | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |